Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Welcome to this half-year interim report for Orexo AB. A quarter and a half year, which has been a bit of a mixed bag with some good progress, but also some areas where we have been surprised by a recent negative development. So I think the headline of today is probably the complete response that we received on OX124 very late on Tuesday evening, and also the press release we had yesterday. We had expected that. We did talk about that in our last quarter report, that we would be delayed, and that it was due to the human factor study and the instructions for use that needed to be updated. However, there were some requests for technical data that came as a surprise and required a little more work from our side. But I will come back to that. But I think the really positive thing is that there was only one issue in the complete response letter regarding the product, and that was related to the instructions for use. And we have completed a new human factor study after updating the instructions for use, which was very successful. So if that had been the only point, we would have been ready to submit that data quite shortly. But now we need to look at some other data requests which are not prompted by issues with the product, but rather by the FDA wanting more certainty around some of the product or device reliability parameters that they are examining. I will also say, because that has been a question I received during the day, that we received a complete response letter. It's not like we have to resend the full file. We have to answer the questions that we received. And with that letter comes very specific guidance on what we need to do to get it approved. So we have identified three areas that have raised concerns. We have already addressed two of those three areas because we were aware of them, and during that process, we were asked by the FDA to provide, for example, instructions for use. So, we were ready to submit that answer. And actually, one of them was submitted just before the approval date. The latest issue, which we discussed in the press release, is new to us and requires our attention, yet we consider it highly manageable and believe we can address it relatively swiftly. But we need more guidance from the FDA before we can come up with a new timeline and guidance on that. Today I am joined by Fredrik Järrsten, who will take us through the financial overview and financial development. I will give a brief update on the business, focusing on both US commercial products under development and a little about our partner products from which we derive royalty income. So, a focus on the key achievements. One thing that is very important for us and important for us long term, and where a lot of focus has been internally, has been to see how the development was for Zubsolv during the quarter after, as you say, a surprisingly low development in Q1 led by the inventory adjustments we saw from the wholesalers in the first quarter. We've seen now during this quarter that Zubsolv is back where we see an alignment between the sales to pharmacies and the wholesalers. Since the sales to pharmacies in the first quarter were actually higher than last year, this trend carried into the second quarter, where we saw higher sales in both dollars and Swedish kronor to wholesalers and also in net sales. Overall, we have a positive EBITDA. We did face some headwinds this quarter because we had to make adjustments and accrue royalties based on what was accrued in the first quarter. We also have this new human factor study that we completed, mostly during the quarter, which had some associated expenses. I'll come back to that a little later. Slight uptick in revenue growth. As I said, we had a very strong rebound from the first quarter compared to last year. It is a slight growth, even though it's down in the low single digits, or 1%. But it is positive compared to last year, and definitely very positive compared to the first quarter, which, as all of you probably noticed, is now delayed. But I will say that based on the feedback we received from the FDA in late April, within two months, we've been able to update the instructions for use. We have conducted a new human factors study, and it has truly been a team effort between the Swedish and the US teams. To the extent that we have had Swedish employees flying over to the US with some of the materials needed for this human factors study, we've had people in the office in the US helping to package the material needed for the study, also involving the movie pipeline. So there's been a strong focus not only on OCS 640, but also on the partnering projects that we have, and here in the partnering projects, we have continued to collect stability data and have seen very impressive data, particularly on large molecules during the quarter. I will also highlight something we have been working on for a long time at Orexo. So that's around sustainability. As you know, we issued a corporate social bond. So we had it rated by Sustainalytics. This has also translated into more focus on the overall ESG sustainability, which has now been reviewed by a company called Equities, which is emerging as one of the leading external or independent assessment companies of sustainability. And we are rated as one of the top 5% of all the 70,000 companies that they have assessed worldwide. We have seen some traction with Zubsolv in Europe. It's coming from a low base, but I think there are a lot of positive developments happening for Zubsolv in Europe, which gives us some hope for the future. We also see that the royalties for Abstral, which we signed ten years ago with what was then ProStrakan, Then it became Gruenthal. Kyowa Kirin, which was then the European arm, was acquired by Gruenthal. Gruenthal has now reviewed the contract. And there are some other countries where we are seeing the contract has expired and will expire during the next 1 to 2 years. So it's very good to see Zubsolv coming in. But of course, we need that to replace some of the Abstral royalties that we have been generating. So a little on the US commercial last quarter, we talked about the very dramatic market events seen both by Orexo and some of our colleagues in the buprenorphine naloxone market. And that was the inventory drop we saw in Q1. So we have seen that it's stabilized, but it remains at the same low level as we exited Q1. So, we haven't seen compensation where inventory levels have increased. But what we've seen now is that the sales from us to wholesalers, from wholesalers to pharmacies, and from pharmacies to patients are aligned. Whereas in Q1 we saw a significant decrease compared to where we were in Q4. What we think drives this is a growing hesitance to carry inventory of controlled substances. Buprenorphine is a controlled substance, and there are significant restrictions on wholesalers and pharmacies regarding how much inventory they can carry. And some of them have taken quite a conservative approach to that. So we think that is one impact. The other one is basically the cost of capital. So, having a high inventory is costing you capital. And by lowering that, you could improve your working capital costs. We have observed a trend that began last year and has continued to accelerate during this quarter. It appears that this increase in Medicaid enrollment, driven primarily by policies implemented during Covid-19, was largely due to automatic renewals of Medicaid enrollment. So patients who were on Medicaid were automatically renewed within Medicaid without having to renew their applications after the withdrawal of the COVID-19 emergency measures. And that means that some of the patients who were on Medicaid have either decided not to apply for new Medicaid insurance, or they have been found not to qualify for Medicaid. And that has triggered the decline in Medicaid. At the same time, we have seen a significant increase in commercial insurance this quarter, with a 19% year-over-year growth. So, the majority of that growth, if you look, appears to be from Medicaid patients now moving into commercial insurance. So rather than driving market growth, there has been some market growth. But a lot of it, we believe, is actually patients shifting from one insurance plan to another. And then there are in the US, there have been a lot of subsidies associated with COVID-19, which have also been reduced as the COVID-19 emergency measures were removed. Taking a more granular look, we showed this picture in the last quarter. And just to give a comparison here, you can see the development in sales to pharmacies and wholesalers where, as you saw, there was a drop in Q1 represented by the dark blue line. Then in Q2, you see that the sales to pharmacies, which is represented by the very stable, slightly yellowish-green line on my computer, at least, is aligned with the blue the line. So, we've observed normalization in inventory during the quarter, which is of course positive long term, particularly as we see sales to pharmacies on a trajectory higher than last year. Across our product range sold, we have seen stabilizing demand as well. So it's not only the inventory that is of course most important; what matters is how the demand actually looks. We still have a very low growth market. It is 3%, just like the last quarter, up 1% since the quarter before last. As I mentioned before, we observed a decline in Medicaid and growth in commercial. And when we look at Zubsolv in particular, we basically saw that we had the same number of prescriptions in the second quarter as we had in the first quarter. That's down 4% from last year. But what is really positive is that we see growth in the commercial segment. Um, that is what we call the open segment. For the first time in five years, we have seen previously exclusive payers, UnitedHealth Group and Humana, grow by 1% from the first quarter. But all in all, the volume is lower year over year. These previously exclusive payers were stable or demonstrated a growth of 1% in Medicaid. We also experienced a decline, albeit less than the market. So we are taking market share in Medicaid. And that is very much driven by some of the continued growth in Medicaid contracts in New York. I can even add here in Indiana where I believe our growth is more than 200% year over year in Indiana. So some comments on the products under development and our partner products. OKX 1 to 4 approval and launch timelines have been extended. And here the issue that we knew was the instructions for use. We have successfully addressed that and that has been documented in a human factor study. So we're ready to submit that back to the FDA. They came with new concerns, and I want to outline them. It's not driven by problems that the product is not delivering, or the quality in the products is insufficient, or the clinical trials are not good enough. This is based on the data that we have generated to show the reliability of the device. And the secondary packaging is meeting the standards for FDA. And to do this, it's customary in the industry to do what you call pilot scale manufacturing. So we take certain manufacturing steps. We do that on a smaller scale than a full commercial scale. And then we are integrating that data into the commercial scale, showing that we don't see a difference between the pilot scale and the commercial scale. Here, the FDA has requested more information on the device part, not on the manufacturing part. It's only on the device part that there is no impact on the device functionality. Moving from the pilot scale to the commercial scale, we found that the data we have submitted was sufficient, but we also respect that the FDA has a different opinion. So now we need to work with the FDA to understand exactly what they are asking for, what kind of data we have to generate to bridge the two, and we will. The process works in such a way now that we will, within the next 30 days, submit what we call a briefing book. And that's basically us proposing how we will address those issues or concerns raised by the FDA. Then we'll have a discussion with the FDA, and we will agree on the path forward. And that will guide how much this is. But since we have not seen any issues in the pilot scale, we don't have any issues documented with the quality. We believe this is more about a documentation part. And of course, the FDA. We have to respect that. They see risk moving from one step to the other. But it is interesting. It was only the device part that concerned them. It was not the CMC personnel at the FDA who had that concern. So we will seek that advice, and that will also guide us on the response. But we are very pleased to see that there are no questions about our clinical trials. There were no questions about the manufacturing process or the quality of our manufacturing partners. So we are quite confident that this is something that we can address relatively swiftly. But there is some uncertainty, as we are not certain about how much data the FDA actually requires. And we need to work on that during the next 30 days. Our pipeline in general is advancing. As I said before, we are working on some of the partnered molecules, which are large molecules. We are working on a partnership with GSK, but we also have a partnership with a vaccine company. A critical point here is to see that we can retain activity in the product at room temperatures or even higher temperatures for large molecules that would otherwise require a cold chain. This approach enables these large molecules to have a completely different distribution path. You can also use the products more broadly than if you had to store them in cold storage. This is beneficial from a patient perspective, a health care perspective, and definitely from the manufacturer's perspective. This is positive, and we hope it will lead to a more established partnership, particularly with GSK and with the vaccine space as we proceed. We have continued to work on refining the formulation, and we're preparing to scale up manufacturing to commercial levels. Our current focus is on OX124, but we are working in parallel to ensure that we can swiftly move into commercial manufacturing. We are now planning a smaller exploratory study to be conducted later this year. Those of you who have been following this closely might recall that last year there was a discussion about allergic rhinitis in some patients. The question is the effect of these nasal sprays on patients with allergic rhinitis. We are now planning to conduct a smaller exploratory study in this group, which could include patients or healthy volunteers. In the fourth quarter, we aim to confirm the effective uptake through the nasal route in this patient group. Importantly, as we launch OX124 with a partner, we are focusing on ensuring it has notable clinical differentiation, particularly in terms of speed of onset. This relates to how much intensity and effect you achieve from the product. We plan to conduct this later this year. Our major competitors have advanced in Europe. They received positive feedback from the scientific advisory board in Europe. This reduced some of the regulatory uncertainty for nasal epinephrine in Europe, which is beneficial in the long term for us, even though it means more competition as other products have a head start. We are continuing discussions with potential partners. The briefing book we approved in the first quarter has evolved into a clinical development plan that we have since presented and discussed with our potential partners. So we continue to be optimistic that we can find a partner to work with during the second half of this year, then on our partner products. Here in Europe, we have seen very good progress in some smaller European markets during the first half of the year, particularly during the second quarter. This has been driven a little by supply issues with other products. But the positive aspect is that when institutions tested Zubsolv, some of them decided to make Zubsolv their preferred choice. So that's very positive in the long term. When they were forced, you could say, to make a switch and test the new product. They saw all the advantages with Zubsolv. One of the issues that we and our partner Accord Healthcare have had for Europe is that our product, which we sell in Europe, is sourced from the US, from a manufacturer we no longer use for US manufacturing. But they are the ones approved for Europe. That means that the cost of goods in Europe right now is much higher than what we pay in the US, and it's not really price competitive in terms of what Accord Healthcare needs to be successful in that commercialization. We work together with Accord Healthcare to reduce the cost of goods. Accord Healthcare has shown a very high commitment in this by investing in the development of a supply chain and manufacturing capacity in Europe for Zubsolv. And we are in the final stages of that, which would enable our partner, Accord Healthcare, to start selling in Europe with a much better cost of goods, which of course will make it much more attractive for the different subsidiaries of Accord to launch the product in our market at a price-competitive level in a price-competitive European market. So we are optimistic. We did see an increase in Zubsolv revenues for Europe during the quarter, but we think that is just the beginning of what hopefully can be a rewarding journey for both us and our partner. Accord Healthcare, on the other hand, our Abstral royalties, as outlined in our reports, we are seeing some markets where the product's contracts expire during 2024 due to patent exclusivity expiring, and also the contract for some markets was a ten-year contract starting in 2014. We have not received a historical breakdown of the different markets, so it has not been possible for us to follow. Exactly when the first launch happened and when the product expires, and how much volume we have by market. Together with our new partner, Sun Pharmaceuticals, who acquired its European subsidiary in 2023. We've now gone through all of the markets and we have a more accurate estimate of the royalties for this year, which has led to an adjustment of the accrued royalties from Q1. Fredrik will comment on that later. We do see that the contracts for some countries in Europe will expire during the remainder of 2024, for some in 2025, but there are other contracts which will actually go on for several years. However, those that are expiring right now are some of the larger volume countries. So we do see that the royalty rates will decline this year, but also in 2025 and beyond. But we are optimistic that with the positive news and subsequent engagement in Europe with lower cost of goods, high commitment, and investment made by Accord to reach that, now good traction in some of the European markets could compensate for the decline in Abstral revenues. With that, I'll leave it to Fredrik to go through the financials.
All right. Thanks a lot. On page 15 we look at revenue. And if we start by looking at the top part of the page, you can see that total revenue in Q2 amounted to 154 million, of that revenue, Zubsolv, sold within US commercial channels, is the main contributor with 148 million for the quarter, and that's slightly up year over year, following especially favorable payer mix, and also supported by a positive impact of 1.1 million from a stronger USD exchange rate in relation to headquarters and pipeline revenues. We had, as Nikolaj just talked about, lower absolute royalties for the quarter due to the negative true-up of accrued royalties that we booked in Q1, and that was based on a partner, Günther Mads reporting. So we had actually accrued $615,000 for Q1. And now the royalty report showed actual royalties of $358,000. So this resulted in a negative adjustment of $257,000 this quarter. And we have then used this lower royalty number of $358,000 as an estimate for Q2 royalties, and as we have talked about before and Nikolaj just discussed, going forward, we can envision a continued gradual decline in royalties, perhaps as agreements for these individual countries expire and a decline in observed royalties, though partly offset by higher sums from non-U.S. revenues related to royalties and sales of tablets to our partner, Accord Healthcare. If you look at Zubsolv specifically in Q2 compared to Q1, you can see in the waterfall graph on the bottom part of the page the following. The negative effects of the inventory adjustment. At the beginning of the year, we had a significant rebound in revenues in Q2 coming from a positive inventory effect, which resulted in lower inventory destocking. You can see in the graph almost 14 million SEK. That is the main explanation why net revenue increased from Q1 by 14.4%. The demand for Zubsolv, expressed in net revenue terms, increased by approximately 1%, as shown in the first three bars, which is the same as for the markets for buprenorphine naloxone. Quarter over quarter. The FX effect was also positive quarter over quarter with 3.7 million. And when you compare with the average FX rate during the quarter. So in conclusion, you will also see in the graph that in total currency, the net revenue from Zubsolv increased by 11.6% between quarters. Next page. Our panel is happy to show a positive EBITDA for the third consecutive quarter. $5,006,000. And also, when doing the exercise that we usually do, adjusting for non-repeating costs, that would imply an EBIT of approximately 13 million. To explain this positive EBIT. First of all, when it comes to cost of goods sold, the majority of the 16.3 million related to the U.S. commercial. Or to be more specific. That is 15.4 million and compared to Q2 last year, we continue to improve our gross margin in the U.S. commercial from 88 to 90%. Second of all, looking at operating expenses in Q2, they were on par with prior year following higher expenses for OX124 developments and launch preparations, higher admin expenses for legal costs related to the DOJ investigation. And now, these expenses, though, were offset by lower R&D costs, especially due to the media study that was finalized in Q3 last year. The U.S. dollar strengthened slightly in the second quarter compared to last year, and the total FX effect on EBIT was a -4 million. So in summary, opex came in at $153.5 million this quarter. Now following U.S. commercial as a segment, the EBITDA contribution from our U.S. business amounted to 47 million for the quarter. That is a margin of 32%, slightly down from 33% last year. The EBIT margin was 24%. Finally, in financial items, we had higher bond loan costs of 21.4 million, of which 8.2 million is non-recurring transaction costs in relation to the refinancing of the old bond and 13.2 million is recurring higher interest expenses for the new bond. We also have an unrealized FX impact of 0.8 million on cash held in US dollars, and lower interest income from bank accounts of 1.1 million. Moving to the next page on cash flow, we can see that liquid funds, that is, cash and cash equivalents, amounted to 140 million in Q2. That's a decrease of 58 million from Q1. But we should not forget that cash flow this quarter was also heavily affected by the settlement of the second and final part of the refinancing of the bond. We have cash flow from operating activities of negative 6.5 million, primarily impacted by negative operating earnings and transaction costs related to the refinancing of the old bond. And that was largely offset, however, by positive changes in working capital.
Investment.
Activities had a negative impact on cash flow. 2.7 million SEK, primarily from investments in equity equipment for the development organization. Financing activities had a negative impact of -48 million. And that's mainly due to the closure of the purchase of 30,000,006 of the new corporate bonds, as well as issuance costs, which are fees to advisors and lawyers for the new bond loan of 12.3 million. Total cash flow for the period was negative fifty-one point five zero seven million. As I said, acquisition of the bond amounted to 30 million. Adding an effect on cash of minus $1.2 million. That results in a decrease in cash of 58 million since the end of Q1. On the next page, we will share our financial outlook for 2023. We first reported that in the Q4 financial statements. Based on current circumstances, we maintain our guidance for 2024 on these metrics. We do see some risks to the subsidiary undertakings revenue guidance with the wholesale inventory adjustment that happened in Q4, although we had a rebound in Q2, it's quite significant. The OpEx and EIBTDA guidance may also be impacted by non-recurring legal expenses associated with the DOJ investigation and a potential settlement, as well as some additional expenses for a resubmission of OX124. So, with the actual present-day explanations you've given, we can conclude these metrics are reaffirmed. And with that, I'll leave. Back to Nikolaj.
Thank you. And just a comment on the expenses here. So with OX124, we don't foresee any major expenses. But of course, there will be expenses that we had not planned for. So this is not like we're looking at significant cost to the OX124. But compared to an approval and a recently finalized human factor study, there will be some additional expenses. Together with the increased legal expenses, and, of course, also Abstral royalties going down slightly. That is reducing the margin, even though we still have a margin to our guidance in the financial metrics. So on the legal update with the patent dispute with Sun Pharmaceuticals, we are waiting for a hearing date from the US Court of Appeals for the Federal Circuit. We understand that they have been under heavy time pressure, and there is a long queue of hearings that they're waiting to schedule. Right now, we haven't received any dates and we wouldn't anticipate this to happen before maybe in the October-November timeframe. But we haven't received a date and there have not been any expenses related to that patent dispute during the quarter, or very, very limited expenses when it comes to the US government investigation or the subpoena. We would very much like to put this behind us, and we are trying to work with our lawyers to find ways to find a resolution on this together with the Department of Justice or the attorney generals from the Western District of Virginia. That is right now that we have a discussion ongoing, but it's very hard to predict where this will end. And the timing of this we have seen during the past four years, particularly we passed the four-year anniversary just a few days ago, and have seen very volatile levels of activity. And now there has been more activity during this quarter. Nevertheless, we know that unpredictable events can happen in the US. And we also know there's an election coming up in the US. And since the attorney general for the district is politically appointed, there could be changes. And who is leading that office could change during the next half year. So it's very hard to predict. It's very frustrating as it's taking a lot of focus away from some people in the organization, particularly in the US, but of course also here in Sweden. So to summarize, where are we right now? I think a very important focus for us is to stabilize Zubsolv revenues. And I think we have been efficient in doing that during this quarter. I'm pretty confident with our financial outlook that we just reported, especially since sales to pharmacies are consistently outperforming last year. So what we are actually talking about here in terms of sales is the wholesaler inventory levels that are hard to predict. And where we had hoped and some of our colleagues in the industry had guided that there would be a rebound in the second quarter. We haven't really seen that. We've noticed that the levels continue to be the same, although they now follow the sales to pharmacies. But we are seeing stable Zubsolv sales, which is crucial. We also had expected to see an approval for OX124 from week 1 to 4 shortly. I think that is still obtainable, but we do need to engage with the FDA to understand exactly what kind of data they are requesting. But again, I want to underline that it is not based on problems we have encountered. It's simply requiring more documentation about how we're bridging between the pilot scale manufacturing and the full-scale manufacturing, and some changes we have done to the packaging device or packaging during the development. Then there is our AmorphOX technology. And here what we are really looking forward to is to see that we can have a partnership in place for AmorphOX. But also to see that the work we are doing with companies like Grünenthal Meds will come into a real development partnership. And what is very encouraging for us here is to see how we continue to improve the stability data and see they are confirming the outstanding value that AmorphOX can bring, in particular to large molecules. We are working also to establish patient support programs for our products. This is something that's important from our sustainability perspective. We're working with our new concept, Match Core, where we have several applications together with healthcare [healthcare] providers in the US, to see if we can find new ways to improve access to treatment for patients in the US, combining pharmaceutical and digital tools. We are working to improve our access to treatment in many different ways and also bringing our products forward. And here we think that, for example, for 640, it will be important for us to find a partnership moving forward. So all in and all, growing commercial revenues and profit contribution are important to have as a foundation. So the growth will come from 1 to 4 when approved and also from future partnership projects. It is to show that we can create a stream of partnerships around the AmorphOX technology and most importantly, that patients get access to our medications. And with that, I will round out our presentation and open up for questions. Thank you.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Klaas Palin from Carnegie. Please go ahead.
Thank you. Uh, hi, and thanks for taking my questions. Uh, and, uh, yeah, I have at least two, uh, maybe more. Uh, my first is related to that. You mentioned that you have initiated launch preparations for OX124 in Q2. Uh, and, uh, just wondering if we should expect such a cost to remain going forward, given the update you have given for FDA and the process.
So on the what we have done, we informed about that in our last quarterly call, we have recruited a very seasoned manager into the organization to lead the OX124 work. Uh, and she has done some market analysis and testing of different concepts around the product. She's also been working on the brand profile, and that I think, is normal work in preparation for OX124. Given where we are right now, I believe that there will still be costs associated. Of course, we have an employee we didn't have in the first quarter. There will be some cost in the second half of the year, but compared to a situation where we had received an approval today, the expenses are of course going to be lower in the second half. And some of the activities that, uh, for example, recruitment of sales personnel is something that we probably delay a little further than what we had planned, until we have more certainty about the timelines for when we can submit the updated data to the FDA.
Yeah. Okay, perfect. Uh, and also, you mentioned that the review period following a resubmission could be either 2 or 6 months. Uh, could you perhaps elaborate on these two alternatives?
Unfortunately, the FDA has not issued any guidance on the difference between 2 and 6 months. And that depends a little on how much work they see that is needed and how many parties are involved. Of course, as we are moving from what we had, if it had just been the human factor study, I would have been more confident that we could do it if we were in the two-month category. But with the new data, it's again hard to predict. And I will say the answer we got from the FDA is not specific in what data, just in what categories of data they're looking at. More documentation. So now it's up to Orexo to come up with a proposal on how we're going to show that in a different way than we have already done. And that will I think the amount of data coming in will define whether it's a 2 or 6 month review time. Unfortunately, I'm not able to give any predictions on that. And we will know, I think, about a month after we have submitted the answer to these questions.
Okay. And then my last one is just about some appeals process. And because you have been talking previously that you expected this hearing to be in the sort of mid-2024, but you don't seem to have a date now. Is there any reason for this? Has the process been delayed or is it just something you need to take into account that these things happen?
I think there are two steps. So the first is that when we received the appeal was first made, then we, that was last summer. So also about a year ago from now, at that time, there's a certain process that we have to follow. And that process took longer, by agreement by the two parties. Then it was delayed over the period over the Christmas time. But also, our counterpart was asking for some extension of timelines. And that has driven some of the time. But the main reason is the workload for the Federal Circuit. A number of companies appealing or number of cases being appealed to the Federal Circuit. In addition, I've heard that they have been rebuilding or they've been doing some renovation of the facilities. So not all of the courtrooms have been available during the last, this during the first half of this year. So there are a lot of different factors playing in. And there's nothing we really can do about it. We're just waiting to get a message that we have been scheduled. So there's nothing in the case. It's more, I think, on the federal circuit with workload and capacity.
Okay.
Understand? Thank you so much for taking my questions.
Thank you, Klaus.
The next question comes from Samya. Devyani from Ark Securities. Please go ahead.
Hi, guys. Thanks for taking my questions. Um, I guess first one is really just on OX124. Um, and maybe some sort of generalization to the business. If we now assume a modest delay to OX124. Um, I'm just trying to work out, in light of individuals cutting their guidance, um, in their recent results in their trading update. And they sort of mentioned that a lot of the revenue comes from a BARDA contract. Have you explored, um, or what's your expectation in terms of when OX124 launches your ability to access those types of government contracts and linking into that? Um, I think, you know, it looks to me excluding a sort of DOJ settlement that you'll have around about $100 million at the end of this year. Is that enough? Um, going into a launch, a new product launch year, or do you think you'd need to raise some further capital? Thanks.
Thank Tribute on the to OX124. Um, within Orexo AB. And so right now, just first I would say the delay is it is hard to predict because we have to talk to the FDA to understand exactly what's needed. And that will drive the amount of work that we need to do. Um, but we do believe we have a decent amount of data available. And we continue to generate data that we believe could be relevant to address some of the questions by the FDA. Then on Indivior and OPI, we have to remember that OPI was. The development of OPI was financed partly by BARDA also, and they buy it for national security reasons. And we do think that within an OPI is quite well suited for that. And that was one of the arguments we have had around weeks to 1 to 4. Also, our product is that due to the long half-life of the product, should someone come up with the dreadful idea of using some of the opioid derivatives like fentanyl, or even stronger versions in some kind of a terror attack or similar, there would be a benefit for having something that has a long half-life. Uh, also for police, SWAT teams, and others who are breaking into manufacturing places, or packaging places. It would be an opportunity to take some as a precautionary measure to ensure that you don't get an overdose when you get in. Uh, I think that that has been part of the strategy for Oregon. Also, one of the reasons why Barda had an interest, of course, was looking at that kind of opportunities. I think products 1 to 4 are quite well suited, particularly for police officers and others. And some of the work we've been doing during the summer is testing different marketing and positioning concepts with institutional buyers, among others. So, when it is approved, we think that this is an opportunity and it's definitely an area where we need to strengthen our organization in comparison to what we have today. Even though Lisa Moore, who has joined us to lead The Voice 1 to 4, has a decent amount of experience from her previous employers. When it comes to our cash position, I think there's a shift. So if you look at this time, there were a lot of financial expenses that are not recurring, and our revenues along with our cash position go very much up and down depending on how much sales we have. And we have significantly higher gross sales compared to our net sales. What we did see in the last quarter was very low inventory exiting the quarter, which contributes to the cash we get paid during the second quarter. So there's a lot of volatility in our cash position if you look historically. So I think to use Q2 as a predictor and just say this is where we go from here is not the right approach. And when we look at the cash flow, I think it's not the right approach. That very much depends on how much we are selling to gross. To how much we're selling to wholesalers. And the other part is that we are looking to do business development agreements, for both product W640 and some of our other molecules. And that, of course, is expected to generate some good income to the company and cash flow. So we are definitely working from a starting point where we should be self-sufficient. And I will also remind them we do have 30 million in the corporate bond that we actually repurchased during the quarter. So those 30 million is something that we could decide to liquidate should we need the additional cash.
Okay. That's great. Can I then just have one follow-up on W640? Um, you've indicated today that you're going to, uh, look at doing an exploratory phase one in Q4. Will you conduct that study? Um, if a partner is not on board by that time?
The answer is yes. We, um, have that approved. And we think that particular question was a focus in the US approval process of nifi. And we think that to show that W640 has similar or superior properties in that patient group is important. It is a relatively small exploratory study and it's not binary in the outcome, because we do know that the product is working. What is important for us is to ensure that the dose we decide to go forward with also falls within the framework, or the high and minimum levels we need to see for approval in the US, and that our formulation is very fast and we want to demonstrate that also for the commercial product.
That's great. Thanks very much.
There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.
We have received a question asking whether we are planning to conduct another study without a partner. And that is different from what we've communicated previously. That is correct. But since the partnering discussions have taken somewhat longer, we have seen this question arise. Allergic rhinitis patients have come into the partner discussions. We think that this is a relatively small task that we can accomplish. One of the things that is important for these small exploratory studies is that we have the manufacturing capacity in-house. So what we need to do is to test it in a smaller group of healthy volunteers. So it's not a large undertaking, but it's something that we believe would be important should we not have a partner in place at that time. But even with a partner, we believe this is very important to ensure we are choosing the right dose when we go into the more pivotal studies and manufacturing of the product next year. Okay. As there are no further questions and we are heading towards the hour, I thank all of you for your participation today and also wish you a good summer. For those of you who have not yet been on vacation, I hope you will have a good vacation. Those of you coming back, I hope you had a good vacation. So thank you a lot for dialing in to this meeting and I wish all of you a good day, but goodbye.



















